tumor lysis syndrome

1:52
MRD negativity as a treatment endpoint in CLL
Arnon Kater
2:43
MURANO update: MRD, biological subsets & safety analysis
John Seymour
2:06
MURANO study: exciting times in CLL
George Follows
3:36
Retrospective multicenter analysis of venetoclax-treated CLL patients
Anthony Mato
4:01
Primary analysis of MURANO study data for R/R CLL
John Seymour
8:06
Combination Treatment with Two Targeted Agents Shows Promise in Previously Treated CLL
Peter Hillmen
1:00
Managing and predicting TLS in CLL patients
Peter Hillmen
5:52
The power of venetoclax
Claire Dearden
3:09
BCL2 inhibition and CLL: the role of venetoclax
Peter Hillmen
1:34
Why venetoclax is a promising new drug for CLL
Paolo Ghia
1:16
Preliminary results of ibruntinib in combination with FCR chemotherapy for CLL
Matthew Davids
0:45
The importance of considering a CLL patient’s tumor lysis risk status
Matthew Davids
1:06
Safety analysis of the BCL-2 inhibitor venetoclax for CLL
Matthew Davids
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals